

ModernGraham Valuation

Bristol-Myers Squibb
Co



Company Name:

Company Ticker BMY

Date of Analysis

6/28/2018

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

| | | | |
|--|--|------------------|------|
| 1. Adequate Size of the Enterprise | Market Cap > \$2Bil | \$91,120,134,661 | Pass |
| 2. Sufficiently Strong Financial Condition | Current Ratio > 2 | 1.52 | Fail |
| 3. Earnings Stability | Positive EPS for 10 years prior | | Pass |
| 4. Dividend Record | Dividend Payments for 10 years prior | | Pass |
| | Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end | -28.96% | Fail |
| 5. Earnings Growth | PEmg < 20 | 27.51 | Fail |
| 6. Moderate PEmg Ratio | PB Ratio < 2.5 OR PB*PEmg < 50 | 7.03 | Fail |
| 7. Moderate Price to Assets | | | |

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

| | | | |
|--|--------------------------------------|------|------|
| 1. Sufficiently Strong Financial Condition | Current Ratio > 1.5 | 1.52 | Pass |
| 2. Sufficiently Strong Financial Condition | Debt to NCA < 1.1 | 1.15 | Fail |
| 3. Earnings Stability | Positive EPS for 5 years prior | | Pass |
| 4. Dividend Record | Currently Pays Dividend | | Pass |
| 5. Earnings Growth | EPSmg greater than 5 years ago Score | | Pass |

Suitability

| | |
|---------------------|------------|
| Defensive | No |
| Enterprising | Yes |

Stage 2: Determination of Intrinsic Value

| | |
|-----------------------------|----------------|
| EPSmg | \$2.01 |
| MG Growth Estimate | 5.79% |
| MG Value | \$40.37 |
| MG Value based on 3% Growth | \$29.15 |
| MG Value based on 0% Growth | \$17.09 |
| Market Implied Growth Rate | 9.51% |

MG Opinion

| | |
|----------------------|-------------------|
| Current Price | \$55.30 |
| % of Intrinsic Value | 136.97% |
| Opinion | Overvalued |
| MG Grade | C+ |

Stage 3: Information for Further Research


| | |
|--|---------|
| Net Current Asset Value (NCAV) | -\$3.37 |
| Graham Number | \$23.30 |
| PEmg | 27.51 |
| Current Ratio | 1.52 |
| PB Ratio | 7.03 |
| Current Dividend | \$1.57 |
| Dividend Yield | 2.84% |
| Number of Consecutive Years of Dividend Growth | 11 |

Useful Links:

[ModernGraham tagged articles](#)
[Google Finance](#)
[Yahoo Finance](#)
[GuruFocus](#)

[Morningstar](#)
[MSN Money](#)
[Seeking Alpha](#)
[SEC Filings](#)

| EPS History | | EPSmg History | |
|---------------------------|--------|---|------------------|
| Next Fiscal Year Estimate | | Next Fiscal Year Estimate | |
| Dec2017 | \$3.34 | Dec2017 | \$2.01 |
| Dec2016 | \$0.61 | Dec2016 | \$1.36 |
| Dec2015 | \$2.65 | Dec2015 | \$1.65 |
| Dec2014 | \$0.93 | Dec2014 | \$1.24 |
| Dec2013 | \$1.20 | Dec2013 | \$1.45 |
| Dec2012 | \$1.54 | Dec2012 | \$1.85 |
| Dec2011 | \$1.16 | Dec2011 | \$2.21 |
| Dec2010 | \$2.16 | Dec2010 | \$2.69 |
| Dec2009 | \$1.79 | Dec2009 | \$2.74 |
| Dec2008 | \$5.34 | Dec2008 | \$2.91 |
| Dec2007 | \$2.62 | Dec2007 | \$1.61 |
| Dec2006 | \$1.09 | Dec2006 | \$1.15 |
| Dec2005 | \$0.81 | Dec2005 | \$1.20 |
| Dec2004 | \$1.52 | Dec2004 | \$1.35 |
| Dec2003 | \$1.21 | Dec2003 | \$1.29 |
| Dec2002 | \$1.59 | Dec2002 | \$1.37 |
| Dec2001 | \$1.06 | Dec2001 | \$1.31 |
| Dec2000 | \$0.95 | Balance Sheet Information 3/1/2018 | |
| Dec1999 | \$1.84 | Total Current Assets | \$14,649,000,000 |
| Dec1998 | \$1.81 | Total Current Liabilities | \$9,624,000,000 |
| | \$1.35 | Long-Term Debt | \$5,775,000,000 |
| | | Total Assets | \$33,083,000,000 |
| | | Intangible Assets | \$7,979,000,000 |
| | | Total Liabilities | \$20,177,000,000 |
| | | Shares Outstanding (Diluted Average) | 1,640,000,000 |





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

**Other
ModernGraham
posts about the
company**

[Bristol-Myers Squibb Co Valuation – September 2017 \\$BMY](#)
[Bristol-Myers Squibb Company Valuation – February 2016 \\$BMY](#)
[27 Companies in the Spotlight This Week – 12/20/14](#)
[Bristol-Myers Squibb Company Annual Valuation – 2014 \\$BMY](#)
[10 Companies in the Spotlight This Week – 12/21/13](#)

**Other
ModernGraham
posts about related
companies**

[Biogen Inc Valuation – June 2018 \\$BIIB](#)
[Mylan NV Valuation – June 2018 \\$MYL](#)
[Amgen Inc Valuation – June 2018 \\$AMGN](#)
[Celgene Corp Valuation – June 2018 \\$CELG](#)
[Allergan PLC Valuation – May 2018 \\$AGN](#)
[Incyte Corp Valuation – April 2018 \\$INCY](#)
[Regeneron Pharmaceuticals Inc Valuation – April 2018 \\$REGN](#)
[Alexion Pharmaceuticals Inc Valuation – April 2018 \\$ALXN](#)
[Vertex Pharmaceuticals Inc Valuation – April 2018 \\$VRTX](#)
[AmerisourceBergen Corp Valuation – April 2018 \\$ABC](#)